Last reviewed · How we verify

Prevention of migraine attacks in adults — Treatment Landscape & Competitive Intelligence

Prevention of migraine attacks in adults (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of migraine attacks in adults, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Rimegepant 75mg every other day dosing rimegepant-75mg-every-other-day-dosing Pfizer calcitonin gene-related peptide receptor antagonist calcitonin gene-related peptide receptor
Rimegepant 75mg daily dosing rimegepant-75mg-daily-dosing Pfizer calcitonin gene-related peptide receptor antagonist calcitonin gene-related peptide receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Prevention of migraine attacks in adults

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of migraine attacks in adults:

Cite this brief

Drug Landscape (2026). Prevention of migraine attacks in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-migraine-attacks-in-adults. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing